NIH Clinical Trial Diversity Act of 2023

Hozzl · 2024-03-13T07:48:06Z

Explore the details of Senate Bill 1701 NIH Clinical Trial Diversity Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/13/2024, 7:48 AM

Summary of Bill S 1701

The NIH Clinical Trial Diversity Act of 2023, also known as Bill 118 s 1701, is a piece of legislation introduced in the US Congress aimed at addressing the lack of diversity in clinical trials conducted by the National Institutes of Health (NIH). The bill seeks to improve the representation of underrepresented populations, including racial and ethnic minorities, women, and older adults, in clinical research studies funded by the NIH.

The Act requires the NIH to develop and implement a plan to increase diversity in clinical trials, including strategies to recruit and retain participants from underrepresented groups. The bill also mandates the collection and reporting of data on the demographic characteristics of clinical trial participants, in order to track progress towards achieving greater diversity.

Additionally, the Act establishes a task force to provide recommendations on how to improve diversity in clinical trials, as well as funding for research on the barriers to participation faced by underrepresented populations. The goal of the legislation is to ensure that clinical research studies funded by the NIH are more inclusive and representative of the diverse population of the United States. Overall, the NIH Clinical Trial Diversity Act of 2023 aims to address disparities in healthcare outcomes by promoting greater diversity in clinical trials, ultimately leading to more effective and equitable treatments for all Americans.

Congressional Summary of S 1701

NIH Clinical Trial Diversity Act of 2023

This bill sets out requirements to increase the diversity of clinical trial participants. The bill also requires other activities to foster participation in clinical trials.

As a condition of funding from the National Institutes of Health (NIH) for a clinical trial investigating a drug or device, a sponsor's application must include certain information related to diversity in its trial, such as goals for recruiting and retaining trial participants and plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements. A sponsor must also annually share demographic data of clinical trial participants with the NIH.

Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1701

Bill S 1701 is currently in the status of Bill Introduced since May 18, 2023. Bill S 1701 was introduced during Congress 118 and was introduced to the Senate on May 18, 2023. Bill S 1701's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of May 18, 2023

Bipartisan Support of Bill S 1701

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1701

Primary Policy Focus

Health

Alternate Title(s) of Bill S 1701

NIH Clinical Trial Diversity Act of 2023

A bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.